Triamcinolone acetonide sustained-release - Flexion Therapeutics

Drug Profile

Triamcinolone acetonide sustained-release - Flexion Therapeutics

Alternative Names: FX-006; Zilretta

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Flexion Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glucocorticoid receptor agonists; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Musculoskeletal pain

Most Recent Events

  • 06 Oct 2017 Registered for Musculoskeletal pain (associated with knee osteoarthritis) in USA (Intra-articular) - First global approval
  • 08 Aug 2017 Flexion Therapeutics completes enrolment in the phase III trial for Musculoskeletal pain (associated with knee osteoarthritis) in USA (Intra-articular)
  • 08 Aug 2017 Flexion Therapeutics plans clinical trials for Musculoskeletal pain (associated with osteoarthritis of the hip and shoulder) by the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top